The rapid global spread of COVID-19 is challenging healthcare systems worldwide, in terms of healthcare planning, infrastructure, and spending. Healthcare professionals are forced to treat severely ill patients with limited access to ventilation equipment, qualified intensive care personnel or protective patient monitoring devices. Since December 2019, novel coronavirus has spread throughout China and across the world, causing a continuous increase in confirmed cases within a short period of time. For instance, according to the World Health Organization Coronavirus Disease (COVID-19) Dashboard (WHO) report, the manifestation of the coronavirus disease (COVID-19) has resulted in over 67 million infected individuals worldwide as of 8th December 2020. Moreover, governments have introduced various measures to encourage social distancing and discourage non-essential travel to limit spread of the disease, in order to reduce infection risk to both National Health Service (U.K.) staff and patients.
Request Here For The Sample Copy Of The Report @ https://www.coherentmarketinsights.com/insight/request-sample/4339
The growing number of product approvals and launches, clinical trials, and mergers and acquisition strategies adopted by key players are the key factors driving growth of the epileptic seizures treatment market.
Growing clinical trials for development of advanced epileptic seizures treatments drugs is projected to augment the epileptic seizures treatment market. For instance, in May 2019, Pfizer Inc. announced that a Phase 3 study to assess the use of Lyrica (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age with primary generalized tonic-clonic (PGTC) seizures did not meet its primary endpoint. Treatment with Lyrica did not result in a statistically significant reduction in seizure frequency versus placebo. Lyrica is not indicated for the treatment of PGTC seizures. The study was a post-marketing commitment to the U.S. Food and Drug Administration (FDA).
The product approvals of advanced epileptic seizures treatments from regulatory bodies is projected to contribute significantly to the epileptic seizures treatment market growth. For instance, in November 2018, GW Pharmaceuticals plc, a global company in the development and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, announced that EPIDIOLEX (cannabidiol) oral solution CV is now available in the U.S. for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older. EPIDIOLEX was approved by the U.S. Food and Drug Administration (FDA) on June 25, 2018, and is the first prescription pharmaceutical formulation of highly purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the ‘high’ felling associated with marijuana, and the first in a new category of anti-epileptic drugs.
The growing adoption of inorganic growth strategies such as mergers and acquisitions by major companies is projected to drive growth of the epileptic seizures treatment market. For instance, in June 2020, UCB acquired Engage Therapeutics, Inc., a clinical-stage pharmaceutical company developing Staccato Alprazolam for the rapid termination of an active epileptic seizure, for US$ 125 million in cash (subject to certain adjustments) and around US$ 145 million in further potential milestone payments related to clinical development, submission and launch of Staccato Alprazolam. Staccato Alprazolam is an investigational drug (Phase 2) developed as a single-use epileptic seizure rescue therapy that combines Staccato delivery technology with alprazolam, a benzodiazepine.
Key Takeaways of the Epileptic Seizures Treatment Market:
- The epileptic seizures treatment market is expected to exhibit a CAGR of 5.4% during the forecast period (2020-2027), due to growing number of product approvals and launches by key players
- Among drug type, third generation segment is expected to hold a major revenue share in 2027, as third generation anti-epileptic drugs are highly prescribed currently, in comparison to first and second generation drugs. Moreover, third generation drugs gain faster approvals from the regulatory authorities. For instance, Lacosamide is one of the drugs in third generation segment, on 17th November 2020, UCB, a global pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved its VIMPAT (lacosamide) CV as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients four years of age and older and VIMPAT injection for intravenous use in children four years of age and older.
- Major players operating in the epileptic seizures treatment market include Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Sanofi S.A., Mylan N.V., Bausch Health Companies Inc., UCB S.A., Eisai Co. Ltd., Abbott Laboratories, Sumitomo Dainippon Pharma Co., Ltd., GW Pharmaceuticals Plc, Marinus Pharmaceuticals, Inc., H. Lundbeck A/S, and Takeda Pharmaceutical Co., Ltd.
Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/4339
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Epileptic Seizures Treatment Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Epileptic Seizures Treatment Industry Impact
Chapter 2 Global Epileptic Seizures Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Epileptic Seizures Treatment (Volume and Value) by Type
2.3 Global Epileptic Seizures Treatment (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Epileptic Seizures Treatment Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Epileptic Seizures Treatment Market Analysis
Chapter 6 East Asia Epileptic Seizures Treatment Market Analysis
Chapter 7 Europe Epileptic Seizures Treatment Market Analysis
Chapter 8 South Asia Epileptic Seizures Treatment Market Analysis
Chapter 9 Southeast Asia Epileptic Seizures Treatment Market Analysis
Chapter 10 Middle East Epileptic Seizures Treatment Market Analysis
Chapter 11 Africa Epileptic Seizures Treatment Market Analysis
Chapter 12 Oceania Epileptic Seizures Treatment Market Analysis
Chapter 13 South America Epileptic Seizures Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Epileptic Seizures Treatment Business
Chapter 15 Global Epileptic Seizures Treatment Market Forecast (2022-2028)
Chapter 16 Conclusions
Direct Buy This Premium Research Report, Click Here @ https://www.coherentmarketinsights.com/insight/buy-now/4339
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027